CMC Biologics Signs License Agreement with Oxford BioTherapeutics

CMC Biologics and Oxford BioTherapeutics sign a non-exclusive license agreement providing OBT with access to CMC Biologics' CHEF1 expression system for R&D and commercial use.

CMC Biologics, a contract biopharmaceutical manufacturing and development organization, and Oxford BioTherapeutics (OBT), a UK-based antibody and biomarker firm, have signed a non-exclusive license agreement providing OBT with access to CMC Biologics' CHEF1 expression system for R&D and commercial use.

CMC's CHEF1 cell line development platform is designed to promote high-level expression of recombinant proteins early in development to allow for rapid isolation of cell lines. OBT plans to use the CHEF1 system for the production of its oncologic therapeutic antibodies.

"Access to the best expression systems is critical for our antibody development team, helping us accelerate production and development of our most promising anticancer agents," s